Cookies used for improved website experience

Siemens Healthineers and our partners use cookies and other similar technologies to operate the Siemens Healthineers websites and personalize content and ads. You may find out more about how we use cookies by clicking "Show details" or by referring to our Cookie Policy.
You may allow all cookies or select them individually. And you may change your consent and cookie preferences anytime by clicking on the "Review and change your consent" button on the Cookie Policy page.

EMCHealthcare_BiographVisionQuadra_2

EMC Healthcare expands its facility with Asia’s first whole-body PET/CT Biograph Vision Quadra from Siemens Healthineers to transform patient care in Indonesia•EMC Healthcare has expanded its facility by acquiring the first Biograph Vision Quadra PET/CT scanner in Asia at Grha Kedoya Hospital, member of EMC Healthcare, marking a major advancement in cancer care in Indonesia.  
 
• The Biograph Vision Quadra enhances patient care with advanced molecular imaging for early disease detection, higher diagnostic accuracy, shorter scan times, and potential to personalized treatment plans. 

• The advanced imaging technology will particularly benefit cancer patients, providing precise, lower-dose imaging and theranostic capabilities for targeted therapies


The World Health Organization (WHO), through the International Agency for Research on Cancer (IARC), has released updated global cancer burden estimates. This data, gathered from 185 countries, reveals that ten types of cancer continue to account for two-thirds of new cases and are the leading cause of death worldwide.

According to the report, there are 20 million new cancer cases globally, with 9.7 million deaths. Lung cancer has the highest incidence rate (12.4%), followed by breast cancer (11.6%), colorectal cancer (9.6%), prostate cancer (7.3%), and abdominal cancer (4.9%)1.

These alarming global cancer statistics underscore the urgent need for advanced diagnostic and treatment technologies to improve patient outcomes. In line with this, EMC Healthcare has taken a significant step in enhancing cancer care in Indonesia by acquiring the first Biograph Vision Quadra in Asia.

The cutting-edge whole-body PET/CT scanner from Siemens Healthineers is poised to transform patient care by delivering advanced imaging for earlier diagnosis and more accurate treatment planning, leading to better outcomes for cancer patients. This investment represents a significant advancement in Indonesia's healthcare services, highlighting EMC Healthcare’s commitment to providing top-tier diagnostic and therapeutic care. 

“This milestone is a testament from EMC Healthcare’s mission to lead the way in healthcare innovation in Indonesia. We are proud to bring this state-of-the-art system to our patients, enabling them to benefit from the most advanced diagnostic tools available today. This marks a new era for precision medicine in the country, particularly for oncology patients who will experience better care and more personalized treatments," said Jusup Halimi, President Director of EMC Healthcare.

PET/CT plays a deciding role in the management of oncology patients: It can detect small lesions like metastasis or secondary tumors. Detecting these tumors is crucial as it can change the patient management. The Biograph Vision Quadra and its advanced molecular imaging capabilities significantly improve small lesion detectability, thereby enhancing diagnostic accuracy, allowing for the earlier detection of diseases, such as cancer, neurological disorders, and cardiovascular conditions, and potentially improving patient outcomes

The system’s 106 cm axial field of view enhances resolution and sensitivity, allowing clinicians to capture detailed insights and dynamically image the average patient from head to thigh in a single scan. With the scanner’s extended axial FoV, the clinician can examine patient anatomy during radiopharmaceutical uptake over time. The combination of True Time-of-Flight capabilities and extended axial FoV permits more anatomical coverage in one bed position than a standard PET/CT scanner, enabling fast scanning at low patient radiation dose.

Additionally, the reduced scan times make the experience more comfortable for patients, particularly for those who are critically ill or undergoing multiple diagnostic procedures. Based on the imaging data, the system allows for the development of precise, patient-tailored treatment plans for advanced therapies like radiology and therapies or theranostics. This is especially beneficial for cancer patients, where the combination of timely and targeted treatment can significantly improve their outcomes.  

“We are delighted to partner with EMC Healthcare in bringing the first Biograph Vision Quadra to Asia. This system represents a new generation of PET/CT imaging, offering unparalleled speed, accuracy, and clinical insights. Patients will receive more precise diagnoses, quicker scans, and personalized treatment strategies that are aligned with the growing focus on precision medicine,” said Alfred Fahringer, Country Head of Siemens Healthineers Indonesia.

This acquisition is expected to transform the clinical landscape of Indonesian healthcare by enabling more accurate diagnostics and more effective treatments. Both Siemens Healthineers and EMC Healthcare are aligned in their vision to expand access to innovative medical technologies, ensuring better patient outcomes across the nation. 

Source: 

1. https://sehatnegeriku.kemkes.go.id/baca/blog/20240506/3045408/kanker-masih-membebani-dunia/ 

About Siemens Healthineers


Siemens Healthineers pioneers breakthroughs in healthcare. For everyone. Everywhere. Sustainably. The company is a global provider of healthcare equipment, solutions and services, with activities in more than 180 countries and direct representation in more than 70. The group comprises Siemens Healthineers AG, listed as SHL in Frankfurt, Germany, and its subsidiaries. As a leading medical technology company, Siemens Healthineers is committed to improving access to healthcare for underserved communities worldwide and is striving to overcome the most threatening diseases. The company is principally active in the areas of imaging, diagnostics, cancer care and minimally invasive therapies, augmented by digital technology and artificial intelligence. In fiscal 2023, which ended on September 30, 2023, Siemens Healthineers had approximately 71,000 employees worldwide and generated revenue of around €21.7 billion. Further information is available at www.siemens-healthineers.com 

Contact for media enquiries, please get in touch with:

Siemens Healthineers Indonesia

Evan Akira Zuraida

Head of Communications, Indonesia

Phone: +62 857 77673585; E-mail: evan.akira@siemens-healthineers.com